Additional file 1 of Impact of clonal hematopoiesis in COVID-19 patients at high risk for adverse clinical outcomes
Creators: name: Smith, Cathy
name: Burugula, Bala B.
name: Jones, Morgan A.
name: Li, Qing
name: Kitzman, Jacob O.
name: Wong, Terrence N.
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Physiology
subject: Pharmacology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences
subject: Computational Biology

description: Additional file 1: Table S1. Genes sequenced using custom smMIPS assay. Table S2. Identified somatic variants with VAF ≥ 2.0% in COVID-19 patients. Table S3. Raw and adjusted associations predicting mortality within 40 days of initial COVID-19 hospitalization at Michigan Medicine in individuals with CH mutations at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting COVID-19 mortality, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. OR = odds ratio. Table S4. Raw and adjusted associations predicting mortality within 40 days of initial COVID-19 hospitalization at Michigan Medicine in individuals with CH having their highest VAF mutation in DNMT3A versus non-DNMT3A genes at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting COVID-19 mortality, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S5. Raw and adjusted associations predicting mortality within 100 days of initial COVID-19 hospitalization at Michigan Medicine in individuals with CH having their highest VAF mutation in DNMT3A versus non-DNMT3A genes at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting COVID-19 mortality, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S6. Raw and adjusted associations predicting pre-existing cardiovascular disease from CH mutations at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting cardiovascular disease, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S7. Raw and adjusted associations predicting pre-existing pulmonary disease from CH mutations at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting pulmonary disease, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S8. Raw and adjusted associations predicting pre-existing CKD from CH mutations at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting CKD, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S9. Raw and adjusted associations predicting pre-existing CKD from CH with their highest VAF mutation in DNMT3A versus non-DNMT3A genes at VAF ≥ 2.0%. Raw univariate odds ratios reflect individual models predicting CKD, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Table S10. Raw and adjusted associations predicting pre-existing CKD from CH with their highest VAF mutation in DNMT3A versus non-DNMT3A genes at VAF ≥ 5.0%. Raw univariate odds ratios reflect individual models predicting CKD, while covariate adjusted multivariate estimates account for all the listed covariates in one full model. Covariate adjusted estimates are Firth corrected.